Ets-1 facilitates nuclear entry of NFAT proteins and their recruitment to the IL-2 promoter
E26 transformation-specific sequence 1 (Ets-1), the prototype of the ETS family of transcription factors, is critical for the expression of IL-2 by murine Th cells; however, its mechanism of action is still unclear. Here we show that Ets-1 is also essential for optimal production of IL-2 by primary...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 110; no. 39; pp. 15776 - 15781 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
24.09.2013
National Acad Sciences |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | E26 transformation-specific sequence 1 (Ets-1), the prototype of the ETS family of transcription factors, is critical for the expression of IL-2 by murine Th cells; however, its mechanism of action is still unclear. Here we show that Ets-1 is also essential for optimal production of IL-2 by primary human Th cells. Although Ets-1 negatively regulates the expression of Blimp1, a known suppressor of IL-2 expression, ablation of B lymphocyte-induced maturation protein 1 (Blimp1) does not rescue the expression of IL-2 by Ets-1-deficient Th cells. Instead, Ets-1 physically and functionally interacts with the nuclear factor of activated T-cells (NFAT) and is required for the recruitment of NFAT to the IL-2 promoter. In addition, Ets-1 is located in both the nucleus and cytoplasm of resting Th cells. Nuclear Ets-1 quickly exits the nucleus in response to calcium-dependent signals and competes with NFAT proteins for binding to protein components of noncoding RNA repressor of NFAT complex (NRON), which serves as a cytoplasmic trap for phosphorylated NFAT proteins. This nuclear exit of Ets-1 precedes rapid nuclear entry of NFAT and Ets-1 deficiency results in impaired nuclear entry, but not dephosphorylation, of NFAT proteins. Thus, Ets-1 promotes the expression of IL-2 by modulating the activity of NFAT. |
---|---|
Bibliography: | http://dx.doi.org/10.1073/pnas.1304343110 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by Laurie H Glimcher, Weill Cornell Medical College, New York, NY, and approved August 9, 2013 (received for review March 5, 2013) Author contributions: H.-W.T., S.-C.M., and I.-C.H. designed research; H.-W.T., T.-S.T., W.T., H.-H.C., and R.G. performed research; H.-W.T., T.-S.T., W.T., H.-H.C., R.G., S.-C.M., and I.-C.H. analyzed data; and H.-W.T., S.-C.M., and I.-C.H. wrote the paper. 1Present address: Merck Serono, Billerica, MA 01821. |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.1304343110 |